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Coronaviruses express open reading frame 1a (ORF1a) and ORF1b polyproteins from which 16 nonstruc-
tural proteins (nsp) are derived. The highly conserved region at the carboxy terminus of ORF1a is processed
by the nsp5 proteinase (Mpro) into mature products, including nsp7, nsp8, nsp9, and nsp10, proteins with
predicted or identified activities involved in RNA synthesis. Although continuous translation and proteolytic
processing of ORF1ab by Mpro is required for replication, it is unknown whether specific cleavage events within
the polyprotein are dispensable. We determined the requirement for the nsp7 to nsp10 proteins and their
processing during murine hepatitis virus (MHV) replication. Through use of an MHV reverse genetics system,
in-frame deletions of the coding sequences for nsp7 to nsp10, or ablation of their flanking Mpro cleavage sites,
were made and the effects upon replication were determined. Viable viruses were characterized by analysis of
Mpro processing, RNA transcription, and growth fitness. Deletion of any of the regions encoding nsp7 to nsp10
was lethal. Disruption of the cleavage sites was lethal with the exception of that of the nsp9-nsp10 site, which
resulted in a mutant virus with attenuated replication. Passage of the attenuated nsp9-nsp10 cleavage mutant
increased fitness to near-wild-type kinetics without reversion to a virus capable of processing nsp9-nsp10. We
also confirmed the presence of a second cleavage site between nsp7 and nsp8. In order to determine whether
a distinct function could be attributed to preprocessed forms of the polyprotein, including nsp7 to nsp10, the
genes encoding nsp7 and nsp8 were rearranged. The mutant virus was not viable, suggesting that the uncleaved
protein may be essential for replication or proteolytic processing.
Coronavirus infections were described as early as the 1930s
and were classified as a distinct family in the 1960s. Since then,
coronaviruses have been isolated from almost all species of
animals tested, including humans. Disease in animals is often
severe and contributes to significant agricultural and economic
loss. Until an emergent coronavirus was identified as the eti-
ological agent of the severe acute respiratory syndrome
(SARS) outbreak in 2003 (14, 30), human coronaviruses were
typically associated with mild upper respiratory tract infections
in winter (23, 37). In addition to the more-severe SARS coro-
navirus (SARS-CoV) (14, 30), two new human coronaviruses
were found to be associated with lower respiratory disease,
NL-63 and HKU-1 (16, 17, 53, 55). Since the SARS epidemic,
new research into coronaviruses has been driven by the desire
to better understand coronavirus replication, pathology, and
mechanisms of host range expansion and has spurred the de-
velopment of anticoronavirus therapies in the event of another
deadly emergence.
Coronavirus replication is mediated by a complex of cellular
and virus-encoded proteins of open reading frame 1 (ORF1),
which comprises the first two-thirds of the viral 27- to 32-kb
positive-strand RNA genome (Fig. 1A). Translation of ORF1
produces two polyproteins designated ORF1a and ORF1ab
(Fig. 1B). The larger of the two polyproteins, pp1ab, is a
carboxyl extension of pp1a that depends upon a 1 ribosomal
frameshift at a pseudoknot structure to read through the trans-
lational stop at the end of ORF1a and translate through
ORF1b (6, 31). For murine hepatitis virus (MHV), the
polyproteins are processed into intermediate and mature non-
structural proteins (nsp) by two papain-like proteinase activi-
ties in nsp3 (PLP1 and PLP2) and by the nsp5 proteinase
(3CLpro or Mpro) (18, 19, 33, 35, 52). Continuous translation
and proteolytic processing of the polyproteins is required for
productive infection, making the proteases attractive targets
for antiviral therapies and suggesting that distinct roles may
exist for both the mature and intermediate precursor forms of
the proteins (5, 11, 29, 32, 45, 56).
The components of the coronavirus replication complex and
their individual roles have been only partially defined. Process-
ing of pp1a and pp1ab by nsp3 and nsp5 of most coronaviruses,
MHV, and SARS-CoV yields 16 nsp proteins that are associ-
ated with the replication complex (Fig. 1B) (19, 40, 47, 48, 59,
60). Although functions have been assigned to many of these
proteins by comparative sequence or biochemical analysis (2,
18, 19, 31), several are either poorly understood or unknown.
In addition to the proteinases, putative or known functions of
ORF1a-derived proteins include hydrophobic transmembrane
domains in nsp3 (TM) (24), nsp4 (MP1), and nsp6 (MP2) that
likely anchor the replication complex to cellular membranes.
An ADP-ribose-1-phosphatase domain has also been identi-
fied in nsp3 (41–43). The proteins encoded by ORF1b have
been associated directly with transcription and replication of
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viral genes. These include the RNA-dependent RNA polymer-
ase (RdRp) in nsp12 (7, 13, 19), a putative zinc-binding do-
main (46), a nucleoside triphosphatase and superfamily 1 he-
licase (Hel) in nsp13 (26, 27, 46), a 3-to-5 exonuclease
(ExoN) in nsp14 (38), an endoribonuclease in nsp15 (1), and
an S-adenosylmethionine-dependent ribose 2-O-methyltrans-
ferase in nsp16 (49).
Among the poorly understood replicase proteins are the
“cassette” of nsp7, nsp8, nsp9, and nsp10 near the 3 end of
ORF1a (Fig. 1B). These proteins are present in all coronavi-
ruses with significant identity and similarity and are processed
by Mpro into mature products of 10, 22, 12.7, and 15 kDa,
respectively. The nsp7 to nsp10 proteins colocalize with the
replication complex and are presumably involved in viral RNA
synthesis (3, 4, 20, 34, 54). Although the exact function of these
proteins is unknown, recent work has provided some insight
into their role in replication. Structural analyses of SARS-CoV
nsp7 and nsp8 demonstrated that the two proteins form a
hexadecameric supercomplex with electrostatic properties fa-
vorable for nucleic acid binding that may function as a proces-
sivity factor for the RdRp (58). nsp8 has also been shown to
possess a low-fidelity primase activity and was proposed to
provide the RNA primers required by the nsp12 RdRp during
replication or transcription (10, 25). The SARS-CoV nsp9 crys-
tal structure has also been resolved and has been shown to
form homodimers possessing single-stranded RNA-binding
properties; it has been suggested that the protein may serve to
stabilize nascent and template RNA during replication, tran-
scription, and processing (9, 15, 51). Putative temperature-
sensitive mutations localized within nsp10 suggest that the
protein may be involved with negative-strand synthesis (45).
Recent reports describing the refinement of the nsp10 struc-
ture have revealed that the protein includes two Zn fingers (28,
36), exhibits nucleic acid-binding affinity (28, 36), and can
crystallize to form a spherical dodecameric structure made up
of 12 nsp10-nsp11 subunits (50) or nsp10 monomers and ho-
modimers (28). Collectively, these data imply that nsp7 to
nsp10 are important in—if not critical to—coronavirus repli-
cation.
In this report we describe the requirements for nsp7 to
nsp10 and their proteolytic processing in MHV replication.
Using the established MHV reverse genetics system (57), we
individually deleted the genes encoding each protein, dis-
rupted each of the cleavage sites associated with nsp7 to nsp10,
and evaluated whether the protein domain was essential for
productive virus infection. For all viable mutants, we charac-
terized virus growth and RNA synthesis in cultured cells, tran-
scription function, and in vitro growth fitness. A potential
second cleavage site at the interface of nsp7 and nsp8 in class
2 coronaviruses was previously identified (Fig. 1C) (34), and
we determined whether ablation of either or both of the pu-
tative cleavage sites affects replication. We also determined
FIG. 1. MHV genome organization, proteolytic processing of the replicase polyproteins, and putative cleavage sites of nsp7 to nsp10. (A) The
5 two-thirds of the MHV genome encode the ORF1 replicase proteins pp1a and pp1ab. ORF2 to ORF7 encode the major structural proteins S,
E, M, and N, along with several accessory proteins. (B) The replicase polyproteins are processed by three proteases to produce 16 mature proteins.
PLP1 is responsible for cleaving between nsp1-nsp2 and nsp2-nsp3 (black arrows), while PLP2 cleaves between nsp3-nsp4 (open circle). Mpro
processes the remainder of the polyproteins (open triangles). The replicase proteins include a number of functionally conserved domains, including
the two PLP proteases, an ADP-ribose-1-monophosphate-processing enzyme (X), three hydrophobic transmembrane domains (TM, MP1, and
MP2), the nsp5 protease (Mpro), RdRp, a putative zinc-binding domain (Z) and helicase (Hel), an exonuclease (ExoN), an endoribonuclease (EU),
and an S-adenosylmethionine-dependent ribose 2-O-methyltransferase (OMT). (C) The amino acid sequences of the Mpro cleavage sites falling
within the nsp7 to nsp10 region of the replicase polyproteins are shown (open arrows denote points of cleavage) along with their P1 Gln amino
acid positions. A second putative cleavage site falling between nsp7-nsp8 is identified with a question mark and a vertical dotted line illustrating
its proposed cleavage site.
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whether the precursor protein containing nsp7 to nsp10 per-
forms a distinct role in viral replication by attempting to rescue
viable virus when rearranging the nsp7 and nsp8 genes within
the infectious clone. This work contributes to the growing body
of data indicating that these small proteins are intimately in-
volved with and critical to viral replication and as such are
attractive targets for research aimed at understanding the in-
tricacies of the coronavirus replication complex and as the
focus of antiviral therapies.
MATERIALS AND METHODS
Cells. Viruses were generated from infectious clones with delayed brain tumor
(DBT) cells and baby hamster kidney cells stably expressing the MHV receptor
(BHK-MHVR), as previously described (57). DBT cells were maintained in
Eagle’s minimal essential medium (MEM) supplemented with 10% fetal clone
II, 5% tryptose phosphate broth, 0.05 g of gentamicin/ml, and 0.25 g of
kanamycin/ml. BHK-MHVR cells were maintained in alpha MEM supple-
mented with 10% fetal calf serum (FCS), 10% tryptose phosphate broth, 0.05 g
of gentamicin/ml, 0.25 g of kanamycin/ml, and 800 g of G418 sulfate (Gene-
ticin; Sigma)/ml.
Assembly of full-length MHV strain A59 (MHV-A59) and mutant infectious
cDNA templates. Viruses were produced from an MHV infectious clone, as
previously described (57). Plasmids containing the viral genome were grown to a
high concentration, isolated, and digested with Esp3I, BglI, or NotI, according to
the manufacturer’s directions (New England Biolabs). Viral cDNA inserts were
visualized in 1% agarose gels in Tris-acetate-EDTA buffer on a Darkreader
(Claire Chemical Research, Denver, CO) and isolated with the QIAquick Gel
Extraction Kit (QIAGEN Inc., Valencia, CA). The concentrations of the indi-
vidual MHV A-G DNA fragments were measured, pooled in stoichiometrically
equivalent amounts to 1 g of total DNA, and ligated with T4 DNA ligase (15
U/100 l) at room temperature overnight in 30 mM Tris-HCl (pH 7.8)–10 mM
MgCl2–10 mM dithiothreitol–1 mM ATP. The ligated products were purified by
phenol-chloroform-isoamyl alcohol (1:1:24) and chloroform extraction, ethanol
precipitated, and resuspended in H2O. Efficient ligation was confirmed by gel
electrophoresis prior to in vitro transcription reactions.
Transcripts of the MHV N gene were coelectroporated with full-length tran-
scripts of the genome. The N gene transcripts were driven from a T7 promoter
at the 5 end of a DNA template generated by PCR from the MHV-G plasmid
with a T7-bearing 5 primer (5-ATGCATTAATACGACTCACTATAGGGAG
AATGTCTTTTGTTCCTGGGCAAG-3) (5T7MHV-N) and a poly(A)-con-
taining 3 primer [5-TCCGGA(TTT)8TTACACATTAGAGTCATCTTCTAA
CC-3] [A59Ng3()].
RNA transfection. Full-length transcripts of MHV-A59 constructs were gen-
erated in vitro with some modification to the manufacturer’s instructions (mMes-
sage mMachine; Ambion, Austin, TX). Reactions were performed for 3 h at 37°C
with 20-l reaction mixtures supplemented with 3 l of a 30 mM GTP stock for
a 1:1 ratio of GTP to cap analog. The transcripts were treated with DNase I,
precipitated in the provided LiCl solution, and resuspended in H2O. Full-length
transcripts were verified by electrophoresis in 0.5% agarose gels in Tris-acetate-
EDTA buffer containing 0.1% sodium dodecyl sulfate (SDS). Subconfluent cul-
tures of BHK-R and DBT cells were trypsinized, washed twice with ice-cold
phosphate-buffered saline (PBS), and resuspended in PBS at 107 cells/ml. Full-
length RNA transcripts were mixed with N gene transcripts and electroporated
into 800 l of the BHK-R cell suspension with three pulses at 850 V and 25 F
in a Bio-Rad Gene Pulser II electroporator. The transfected BHK-MHVR cells
were diluted 1:10, 1:100, and 1:1,000 in 5-ml volumes of fresh medium, mixed
with 105 DBT cells, seeded in 60-mm-diameter cell culture dishes, and incubated
at 37°C. Three hours later, the medium was removed from each dish and re-
placed with 5 ml of 1% agarose melted in 10% FCS-MEM. The overlaid plates
were then incubated at 37°C in 5% CO2 and checked for plaques the next day.
Plaques were isolated at 24 or 48 h postelectroporation and amplified on DBT
monolayers in 60-mm-diameter cell culture dishes. The virus-containing medium
was removed 18 to 24 h postinfection (hpi), aliquoted, and frozen at 70°C until
being titered. RNA was isolated from the monolayers for sequence analysis of
the plaque-purified viruses by reverse transcription (RT)-PCR. If plaques were
not visible by 72 h postelectroporation, the transfection was repeated and the
cells were transferred to a single 75-cm2 flask with 105 DBT cells and passaged
1:10 (cells and medium) every 2 to 3 days. RNA was extracted from cells during
each passage and analyzed for leader-containing transcript.
Cloning of MHV deletion and cleavage mutants. Overlapping PCR was em-
ployed for construction of mutant cDNA templates. Mutations were introduced
with two rounds of PCR. The first round generated two amplicons, which were
then fused by a second round of PCR using the 5 primer for amplicon 1, the 3
primer of amplicon 2, and the two overlapping amplicons for a template. The
first round of PCR consisted of 35 cycles of 94°C annealing for 30 s, 55°C
annealing for 30 s, and 68°C extension for 30 s. The second round of PCR
increased the extension time to 1 min. The fused, overlapped PCR products were
purified (PCR Purification Kit; QIAGEN), digested at two unique restriction
sites, purified a second time (PCR Purification Kit), and ligated into a similarly
digested MHV plasmid. Primers, template DNAs, restriction sites, and the plas-
mid backbone into which the PCR product was ligated are provided in Table 1.
Mutations inserted into the MHV infectious clone were verified by sequence
analysis.
Rearrangement of the nsp7 and nsp8 genes. DNAs encoding rearranged nsp7
and nsp8 genes were synthesized (Bio Basic Inc., Ontario, Canada), digested with
PstI and HindIII according to the manufacturer’s instructions (New England
Biolabs), and ligated into the similarly digested MHV-D plasmid. The mutated
template was verified by sequence analysis and assembled as part of the infec-
tious clone.
Plaque assay titration of virus titer. DBT cells in 60-mm-diameter cell culture
dishes (106 cells) were infected with 200 l of serially diluted virus in PBS.
After 1 h of incubation at 25°C, cells were washed three times with PBS, overlaid
with 5 ml of 1% agarose melted in 10% FCS-MEM, and incubated at 37°C in 5%
CO2. The next day, plates were stained with neutral red and plaques were
counted.
RT-PCR verification of nonviable mutants. Mutants failing to generate
plaque-forming viruses were tested for the ability to generate leader-containing
transcripts, whose presence would indicate at least low levels of replication even
in the absence of cytopathic effects. RNA harvested from passaged cells was used
as a template for generating cDNA by reverse transcription using Superscript II
(Invitrogen) and random hexamers (Invitrogen), according to the manufacturer’s
instructions. Following cDNA synthesis, PCR was completed with primers
MHV-4 (5-AAGAGTGATTGGCGTCCGTA-3), which anneals to the leader
sequence of MHV, and 30019c (5-GCAGTAATTGCTTCTGCTG-3), which is
complementary to the N gene. Simultaneous PCRs for GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) were also run as RNA quality and RT controls
using primers GAPDHF (5-CATGGGGAAGGTGAAGGTCG-3) and GAP
DHR (5-TTGATGGTACATGACAAGGTGC-3).
Northern blot analysis. DBT cells in 60-mm-diameter cell culture dishes (106
cells) were infected with MHV-A59 or one of the recombinant viruses at a multi-
plicity of infection (MOI) of 0.05. At 12 hpi, intracellular RNA was isolated with
TRIzol reagent (Invitrogen), as directed by the manufacturer, and 0.05 g of total
mRNA was treated with glyoxal and separated on agarose gels using NorthernMax-
Gly according to the manufacturer’s directions (Ambion). The RNA was transferred
to BrightStar-Plus membrane (Ambion) for 3.5 h and then cross-linked to the
membrane by UV light. The blot was prehybridized and probed with a labeled RNA
complementary to 200 bp of the 5 portion of the N gene. The RNA probe was
generated by PCR using primers MHV-5N (5-ATGTCTTTTGTTCCTGGGCA
AG-3) and T7-30019c (5ATATATTAATACGACTCACTATAGGGAGACCA
GAAAACCAGGAGTAATGG-3). RNA transcripts were driven from the T7 pro-
moter included in the 3 primer. RNA was biotinylated with the BrightStar Psoralen-
Biotin Nonisotopic Labeling Kit, as directed by the manufacturer (Ambion).
Following prehybridization, blots were hybridized overnight and washed with low-
and high-stringency buffers, as recommended by the manufacturer (Ambion). Filters
were incubated with the chemiluminescent substrate CDP-STAR (Ambion). The
blots were overlaid with film and developed.
Radiolabeling of MHV proteins and immunoprecipitation of cell lysates. DBT
cells in 60-mm-diameter cell culture dishes (3  106 cells) were infected with
MHV or one of its mutants or were mock infected with PBS. At 4.5 hpi, the
medium was replaced with fresh 5% FCS-DMEM lacking methionine and cys-
teine and containing actinomycin D (20 g/ml). At 6 hpi, [35S]methionine-
cysteine (100 Ci/ml) was added and the mixture was incubated at 37°C for 3 h.
Cells were washed with 1 M Tris and then lysed in 1 ml of lysis buffer (150 mM
NaCl, 1% NP-40, 0.5% deoxycholate [DOC], 50 mM Tris [pH 8.0]). Immuno-
precipitations were performed in a final volume of 1 ml with protein A-Sepha-
rose beads (Sigma), 100 l of radiolabeled lysate, and 2 to 10 l of polyclonal
antiserum specific for one of the nsp7 to nsp10 proteins (4) after the lysate was
boiled for 5 min in 1% SDS in buffer C (150 mM NaCl, 1% NP-40, 1% DOC, 1%
SDS, 10 mM Tris [pH 7.4]). Protein-bead conjugates were washed three times in
the buffer used for immunoprecipitations, and the proteins were eluted from the
beads, followed by boiling for 5 min in 2 protein loading buffer (200 mM
dithiothreitol, 100 mM Tris [pH 6.8], 0.04% bromophenol blue, 20% glycerol).
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The proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE)
in 5 to 18% polyacrylamide gradient gels and analyzed by fluorography. The 14C
high-molecular-weight standard (Gibco) and full-range rainbow marker (Invitro-
gen) were used as molecular weight standards.
Statistical analysis. Statistical differences between the titers of viruses, ex-
pressed as P values, were calculated with Student’s t test.
Immunofluorescence assays and confocal microscopy. DBT cells grown on
glass coverslips were infected with MHV or mock infected with PBS and then
rocked at 25°C for 30 min. Following virus adsorption, the infected medium was
replaced with fresh, prewarmed 10% FCS-MEM and the cells were incubated at
37°C. At 8 hpi, the cells were fixed and permeabilized with 100% methanol
cooled to 20°C. Indirect immunofluorescence assays were performed as previ-
ously described (4). Secondary antibodies conjugated to fluorophores were used
at a 1:1,000 dilution and included anti-guinea pig Alexa 546, anti-rabbit Alexa
488, and anti-mouse Alexa 633. Immunofluorescence was detected with a Zeiss
LSM 510 laser scanning confocal microscope with a 40 oil immersion objective.
Image analysis and merging were performed with Adobe Photoshop, version 7.0.
RESULTS
Viability of nsp7 to nsp10 deletion mutants. Mpro targets
amino acid sequences (L, F, I)Q2(S, N/A) and cleaves after
the essential Gln at position 1 (P1) (31). The nsp7 to nsp10
protein domains were individually deleted from the MHV ge-
TABLE 1. Primers, template DNAs, and restriction sites used in the generation of deletion and cleavage mutants
Mutant Amplicon Primer Primer name Sequence (533) Template DNA Restriction sites
nsp7 1 5 D 3500 CGGAGGCTTTTGACTTTCTG MHVD PstINdeI
3 D 470c AATTTGAGATACTTCAATGACTGG
2 5 5nsp7 GTATCTCAAATTCAAAGTGAATTTGTTAATA
TGGC
MHVD
3 D 1001c GCAGACACTACCTTACTCTTC
nsp8 1 5 D 3500 CGGAGGCTTTTGACTTTCTG MHVD PstIHindIII
3 D743c TAAGGCTTGCAAGACAGTATTGTC
2 5 5nsp8 GTCTTGCAAGCCTTACAGAACAATGAGTTGAT
GCCTCAG
MHVD
3 D 1570c CAGTTACGCTGGAGTCTG
nsp9-D 1 5 D 880 CAGCAGATTAAGCAGCTAG MHVD HindIIINdeI
3 D 1328c CAAAACAACAGTAGACACTTC
2 5 5nsp9-D CTACTGTTGTTTTGCAGCCTAAGAGACGAAG
GGCG
MHVD
3 D 1769c GCGCTCTGCTGAAGCCAG
nsp9-E 1 5 E 4031 CCACGCTGATGAGCTTTACC MHVE ClaIMscI
3 E 1c TAGGAGAGACGAAGGGC
2 5 5nsp9-E CCTTCGTCTCTCCTAGCGGGTACGGCAACTGAG MHVE
3 E 462c CCATCAACATCTGGATGTTC
nsp10 1 5 E 4031 CCACGCTGATGAGCTTTACC MHVE ClaIKpnI
3 E 199c CAATCTCACTGTCGAGG
2 5 5nsp10 CGACAGTGAGATTGCAGTCAAAAGACACGAAC
TTTTTAAACG
MHVE
3 E 1021c CATTGCGGTCAAAATGACGC
nsp6*7 1 5 D 3500 CGGAGGCTTTTGACTTTCTG MHVD PstINdeI
3 D 470c AATTTGAGATACTTCAATGACTGG
2 5 QAnsp6/7 GTATCTCAAATTGCATCAAGATTGACG MHVD
3 D 1001c GCAGACACTACCTTACTCTTC
nsp7*8 1 5 D 3500 CGGAGGCTTTTGACTTTCTG MHVD PstINdeI
3 D 1328c CAAAACAACAGTAGACACTTC
2 5 QAnsp7/8 CAAGCCTTAGCGAGTGAATTTGTTAATATG MHVD
3 D 1001c GCAGACACTACCTTACTCTTC
nsp8*9 1 5 D 880 CAGCAGATTAAGCAGCTAG MHVD NdeIHindIII
3 D 1328c CAAAACAACAGTAGACACTTC
2 5 QAnsp8/9 CTACTGTTGTTTTGGCGAACAATGAGTTGATGC MHVD
3 D 1570c CAGTTACGCTGGAGTCTG
nsp9*10 1 5 E 4373 GTTCGGTGTAGGTCGTTC MHVE ClaIMscI
3 E 199c CAATCTCACTGTCGAGG
2 5 QAnsp9/10 GTGAGATTGGCGGCGGGTACGG MHVE
3 E 462c CCATCAACATCTGGATGTTC
nsp10*11 1 5 E 4031 CCACGCTGATGAGCTTTACC MHVE ClaIKpnI
3 E 606c GCAAACTGGGAGCCTGTGCCTAC
2 5 QAnsp10/nsp11 CCCAGTTTGCGTCAAAAGACACG MHVE
3 E 1021c CATTGCGGTCAAAATGACGC
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nome while preserving functional cleavage sites by fusing the
N-terminal P1 amino acid to the carboxyl P1 residues of the
flanking proteins (Table 2). Virus was produced from cDNA
templates as previously described (57), and viability was deter-
mined by syncytium formation in cells electroporated with in
vitro-transcribed mutant genome RNA. All of the deletion
mutants failed to yield virus or produce viral cytopathic effect.
A series of MHV temperature-sensitive mutants which grow
only at a lower permissive temperature have been described
(45). With this in mind, a second attempt to generate nonviable
viruses was made, and electroporated cells were incubated at
32°C instead of 37°C. However, none of the deletion mutants
demonstrated the temperature-sensitive phenotype; no viable
viruses were detected at 32°C even after several passages span-
ning at least a week, and no leader-containing transcripts in-
dicative of subgenomic mRNA synthesis were detected in
transfected cultures by RT-PCR, indicating that these dele-
tions were truly lethal for replication.
Viability of cleavage site-disrupted mutants. To evaluate the
requirement of nsp7 to nsp10 proteolytic processing for virus
replication, cleavage sites flanking nsp7, nsp8, nsp9, and nsp10
were individually disrupted by replacing the P1 Gln with Ala
(Table 3). There are two potential cleavage sites at the nsp7-
nsp8 interface, an LQ2A and an LQ2S (present at positions
P5-P3 and P2-P1, respectively, in Table 1). Although the
LQ2S site has been shown to be cleaved during nsp7-nsp8
processing (34), it is possible that the upstream LQ2A site is
also functional. To address this possibility, both sites were
substituted, either individually (MHV7/8A and MHV7/8B) or
in combination (MHV7/8AB).
Full-length cDNAs of each of the seven cleavage site
mutants were assembled by standard techniques, and tran-
scripts were electroporated into cells. Viability was deter-
mined by syncytium formation. For viruses that failed to
produce syncytia, the possibility of low-level replication in
the absence of syncytium formation was tested by RT-PCR
specific for subgenomic mRNAs produced during coronavi-
rus replication. This test was performed on cells collected
during three sequential passages of the electroporated cells
(Fig. 2). Following electroporation of mutant genome RNA
into cells, no syncytia or subgenomic mRNA was detected
for mutants MHV6/7, MHV7/8AB, MHV8/9, and MHV10/
11. A second attempt to generate nonviable viruses was
made with incubations at 32°C, but none of the cleavage
mutants failing to grow at 37°C were rescued by growth at
the lower temperature. These data indicated that disruption
of the cleavage sites at nsp6-nsp7 and both sites at nsp7-
nsp8, nsp8-nsp9, and nsp10-nsp11 were lethal for viral rep-
lication. In contrast, disruptions of either the nsp7-nsp8 or
nsp9-nsp10 cleavage sites were not lethal, and recombinant
viruses of each were plaque purified for future use. Plaque
morphologies of MHV7/8A and MHV7/8B were similar to
those of the wild type, but MHV9/10 displayed a small-
plaque phenotype (data not shown). Sequence analysis of
RNA from virus-infected cells demonstrated the presence of
the appropriate mutations in each of the viable viruses.
TABLE 2. nsp7 to nsp10 cleavage sites for wild-type MHV and deletion mutants
Protein
Amino acid sequence of indicated cleavage site
P5 P4 P3 P2 P1 P1 P2 P3 P4 P5
Wild type
nsp6-nsp7 V S Q I Q S R L T D
nsp7-nsp8 L Q A L Q S E F V N
nsp8-nsp9 T V V L Q N N E L M
nsp9-nsp10 T V R L Q A G T A T
nsp10-nsp11 G S Q F Q S K D T N
Mutant
nsp7 V S Q I Q S E F V N
nsp8 L Q A L Q N N E L M
nsp9 T V V L Q A G T A T
snp10 T V R L Q S K D T N
TABLE 3. Mutagenesis of the nsp7 to nsp10 cleavage sites
Virusa
Mutation of P1 (Q to A) at cleavage sitesb
P5 P4 P3 P2 P1 P1 P2 P3 P4 P5
MHV6/7 V S Q I A S R L T D
MHV7/8A* L A A L Q S E F V N
MHV7/B† L Q A L A S E F V N
MHV7/8AB‡ L A A L A S E F V N
MHV8/9 T V V L A N N E L M
MHV9/10 T V R L A A G T A T
MHV10/11 G S Q F A S K D T N
a Symbols: *, the upstream LQ2A site is substituted; †, the downstream LQ2S site is substituted; ‡, both sites are substituted.
b Boldface type, introduced Ala.
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Growth kinetics of viable viruses were compared to those of
wild-type MHV in DBT cells at an MOI of 0.05 PFU/cell
(Fig. 3A). MHV, MHV7/8A, and MHV7/8B reached com-
parable peak titers at 18 hpi of 7.4 	 0.1 (mean 	 standard
deviation), 7.3 	 0.2 (P 
 0.2), and 7.4 	 0.1 (P 
 0.8) log10
PFU/ml, respectively. The MHV9/10 mutant displayed an
attenuated growth phenotype, with peak titers almost 2 logs
lower than those of MHV (P  0.0001), of 5.5 	 0.1 log10
PFU/ml at the 18-h point.
Stability of the replication-attenuated MHV9/10 mutation
was tested by successive blind serial passages on DBT cells for
15 passages, followed by 3 plaque purification of the resulting
virus. The growth kinetics of two passage 15 isolates,
MHVp15-1 and MHVp15-3, were compared to those of MHV
(Fig. 3B). In contrast to the parent mutant virus, the passage 15
isolates displayed near-wild-type growth kinetics in DBT cells:
MHVp15-1 and MHVp15-3 reached peak titers of 6.8 	 0.1
and 6.9 	 0.1 log10 PFU/ml, respectively, which approached
that of the 7.2 	 0.1 log10 PFU/ml for MHV.
Sequence analysis of the nsp7 to nsp10 region of the rever-
FIG. 2. RT-PCR verification of the replication deficiency of non-
syncytium-forming cleavage mutant viruses. RNA was extracted from
cells over three passages of electroporated DBT cells and superna-
tants. PCR was completed with primers specific for leader-containing
N gene transcripts and GAPDH as a control for RNA quality and
successful RT reactions. RNA from cells infected with wild-type MHV
was used as a positive control.
FIG. 3. Replication kinetics of viable cleavage mutants and MHV9/10 revertants. (A) Comparison of growth curves for MHV (black circle and
solid line), MHV7/8A (black square and solid line), MHV7/8B (black triangle and dashed line), and MHV9/10 (black circle and dashed line).
(B) Replication fitness of revertant MHV9/10 passage 15 viruses. Growth curves compare MHV (black circle and solid line) to the passage 15
isolates MHVp15-1 (black square and solid line) and MHVp15-3 (black triangle and dashed line). Growth curves were performed on DBT cell
monolayers infected at an MOI of 0.05 PFU/cell. Supernatants were sampled for replicating virus at 0, 6, 12, 18, and 24 hpi, and titers were
determined by plaque assay. Data points represent the average of three replicate experiments, and error bars show the standard deviation. The
limit of detection (lod) is represented by a horizontal dashed line at 1.7 log10 PFU/ml.
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tant viruses illustrated that the inserted mutation did not revert
to wild-type sequence at the nsp9-nsp10 cleavage site. Two
patterns of mutations were found. Three of the six plaque
isolates sequenced, including MHVp15-1, had mutated the
guanosine at nucleotide 13164 to an adenosine, changing the
introduced alanine at P1 of the nsp9-nsp10 cleavage site to a
threonine (Table 4). The other mutants, including MHVp15-3,
maintained the alanine at the P1 position but had a guanosine
instead of an adenosine at nucleotide 13102, producing an
arginine instead of a lysine 21 amino acids upstream of the
nsp9-nsp10 P1 position.
Three mutants were constructed to determine whether the
changes found in nsp9 of the passage 15 isolates could be
attributed to improved fitness of the viruses (Table 4). The
engineered mutant MHVQ4319T contained the P1 Gln4319Thr
substitution, reproducing the nsp9 sequence found in
MHVp15-1. In order to determine whether the Lys4298Arg
substitution in nsp9 identified in MHVp15-3 affects viral rep-
lication in DBT cells, the single mutation was introduced in the
wild-type infectious clone and used to produce the mutant
virus MHVK4298R. The final mutant, MHV9/10K4298R, pos-
sessed the nsp9 Lys4298Arg substitution in addition to the P1
Gln4319Ala substitution introduced to disrupt nsp9-nsp10
cleavage, giving it an nsp9 sequence identical to that of
MHVp15-3. Viable viruses were recovered for all three, and
the growth curves of the plaque-purified viruses indicated that
the none of the changes in nsp9 of MHVp15-1 or MHVp15-3
were solely responsible for the improved growth kinetics of the
passage 15 revertants (Fig. 4). MHVQ4319T reached a titer of
6.3 	 0.2 log10 PFU/ml at 30 hpi, comparable to that of
MHV9/10 at 6.0 	 0.4 (P 
 0.3) and indicating that the nsp9
mutation found in MHVp15-1 was not responsible for its im-
proved fitness relative to the attenuated parent. Introduction
of Lys4298Arg into the MHV backbone did not reduce the
peak titer of the virus; MHVK4298R attained a titer of 7.5 	 0.1
log10 PFU/ml at 30 hpi, which was comparable to the wild-type
titer of 7.4 	 0.1 (P 
 0.4). The combination of K4298R and
Q2319T found in the nsp9 protein of MHVp15-3 was not
sufficient to return the mutant MHV9/10K4298R to a wild-type
growth level (P  0.0001 [at 30 hpi]). Although attaining a
peak titer only at 30 hpi comparable to that of MHV9/10 (P 

0.1), the MHV9/10K4298R virus maintained better growth than
the parent mutant from 12 to 24 hpi. MHV9/10K4298R dis-
played higher average titers than did MHV9/10: 5.1 	 0.2 (P 

0.0007), 6.1 	 0.1 (P 
 0.0007), and 6.4 	 0.1 (P 
 0.004) log10
PFU/ml at 12, 18, and 24 hpi, respectively. In comparison,
MHV9/10 had titers of 3.7 	 0.2, 4.7 	 0.3, and 5.4 	 0.3 log10
PFU/ml at the same time points. The mutation(s) responsible
for the increased in vitro fitness of the serially passaged virus at
least requires the contribution of more-distal mutations within
the genome that remain to be identified.
Rearrangement of nsp7 and nsp8. The domain order of
coronavirus ORF1ab nsp proteins is conserved. However, it
has been possible to recover mutant viruses with deletions and
rearrangements of nsp2 (21; also unpublished data). To test
whether the nsp7 to nsp10 order must be maintained for effi-
cient replication, the nsp7 and nsp8 genes were rearranged.
Transcripts were driven from the cDNA templates and elec-
troporated into cells. Viability was determined by syncytium
formation and detection of leader-containing transcripts by
RT-PCR of RNA harvested at each of three passages. Follow-
ing electroporation of cells with mutant genome RNA contain-
FIG. 4. Characterization of the nsp9 genetic components of
MHVp15-1 and MHVp15-3. Shown is a comparison of MHV (black
circle and solid line), the attenuated parent virus MHV9/10 (black
square and solid line), MHVQ4319T (black triangle and dotted line),
MHVK4298R (black square and dotted line), and MHV9/10K4298R
(black circle and dotted line). Growth curves were performed on DBT
cell monolayers infected at an MOI of 0.05 PFU/cell. Supernatants
were sampled for replicating virus at 0, 6, 12, 18, and 24 hpi, and titers
were determined by plaque assay. Data points represent the average of
three replicate experiments, and error bars show the standard devia-
tion. The limit of detection (lod) is represented by a horizontal dashed
line at 1.7 log10 PFU/ml.
TABLE 4. Genomic variations in nsp9 among MHV, MHV9/10,
and the passage 15 mutants
Virus
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ing the nsp8-nsp7 rearrangement, no virus was obtained and no
leader-containing transcripts were detected, suggesting that
the domain orders for nsp7, nsp8, and perhaps the other
components of the precursor polyprotein were essential for
replication.
Verification of ablated cleavage sites in viable mutant vi-
ruses. Processing of the ORF1a nsp8, nsp9, and nsp10 repli-
case proteins was evaluated in DBT cells infected at an MOI of
1, treated with actinomycin D at 4.5 hpi, and radiolabeled from
6 to 9 hpi. Immunoprecipitation using either anti-nsp8 anti-
body (for the MHV7/8 mutants) or anti-nsp9 and anti-nsp10
antibody (for the MHV9/10 and passage 15 mutants) (3) was
used to evaluate the impact of the specific cleavage site muta-
tions on ORF1a polyprotein processing. Substitution of the P1
Gln to Ala prevented processing at the cleavage sites for the
MHV9/10, MHVp15-1, and MHVp15-3 viruses (Fig. 5). Nor-
mal processing of nsp8 (22 kDa), nsp9 (12 kDa), and nsp10 (15
kDa) was detected during wild-type MHV infection but not in
mock-infected cells. In contrast, nsp10 was absent following
MHV9/10 and MHVp15 infection. However, a slower-migrat-
ing band of approximately 27 kDa, which is the predicted size
for an nsp9-nsp10 fusion protein, was present in the mutants
but absent in the wild-type controls. These data indicate that
neither the nsp9 P1 Ala110Thr substitution in MHVp15-1 nor
the nsp9 Lys89Arg change in MHVp15-3 restored cleavage at
the nsp9-nsp10 junction.
Analysis of MHV7/8A- and MHV7/8B-infected cultures in-
dicated that both the LQ2A and LQ2S sites bordering the
nsp7-nsp8 junction are functional cleavage sites. Following im-
munoprecipitation, 22-kDa proteins were precipitated with
anti-nsp8 antibody for the wild-type control, MHV7/8A, and
MHV7/8B. Notably, the immunoprecipitated protein from
MHV7/8B had slightly slower migration than that of the con-
trol or the MHV7/8A mutant, consistent with the prediction
that the LQ2A site was cleaved and yielded an nsp8 protein
that was 3 amino acids larger (366 Da) than that of the
LQ2S cleaved protein.
Transcriptional profile of viable mutant viruses. With the
exception of the attenuated MHV9/10 mutant, viable mutants
were found to be similar to MHV in their transcriptional ac-
tivities and generation of subgenomic RNA (Fig. 6). To deter-
mine whether differences in RNA synthesis were associated
with the different growth phenotypes, cultures of DBT cells
were infected with the mutant panel at an MOI of 0.05 and
total intracellular RNA was harvested at 12 hpi. Northern blots
hybridized with an RNA probe complementing the 5 end of
the N gene showed no differences in either the pattern or
relative amounts of subgenomic to genomic RNA in most
mutants compared to control virus. Consistent with the re-
duced growth of the mutant virus in vitro relative to that of
MHV, MHV9/10 had significantly reduced amounts of RNA,
with only the mRNA 6 and 7 bands clearly resolved. Impor-
tantly, revertant viruses had restored efficient growth kinetics
and transcription of full-length and subgenomic mRNAs. We
FIG. 5. ORF1a polyprotein processing in recombinant viruses. Cul-
tures of cells were infected with MHV, MHV7/8A, MHV7/8B, MHV9/10,
MHVp15-1, or MHVp15-3 for 4.5 h. The cultures were radiolabeled for
3 h, and antisera against nsp8 (22 kDa), nsp9 (12 kDa), or nsp10 (15 kDa)
was used for immunoprecipitation. DBT cells were infected at an MOI of
1 PFU/cell and labeled with [35S]Met/Cys-containing medium from 6 to 9
hpi in the presence of actinomycin D. At approximately 9 hpi, cells were
lysed and proteins were immunoprecipitated with polyclonal sera against
nsp8, nsp9, or nsp10 and then resolved by SDS-PAGE and identified by
fluorography. Bands corresponding to nsp8, nsp9, nsp10, and the fused
nsp9-nsp10 (nsp9-10) are indicated. The protein corresponding to nsp8
isolated from MHV7/8B-infected cells () migrated slower than those of
MHV or MHV7/8A.
FIG. 6. RNA synthesis in recombinant and wild-type viruses. Cul-
tures of cells were infected with wild-type MHV or recombinant vi-
ruses, and intracellular RNA was harvested from DBT cells at 12 hpi.
RNA was separated on a 1% agarose gel, transferred to nylon filters,
and hybridized with a biotinylated RNA probe specific for N protein
mRNA. The filters were incubated with a chemiluminescent substrate
and exposed on film.
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did not identify any significant differences in the relative molar
ratios of the viral-plus-sensed RNAs (data not shown).
Association of mutant proteins with replication complexes.
The distribution of the mutant proteins within cells was com-
pared to their wild-type counterparts. The nsp7 to nsp10 pro-
teins are known to colocalize with sites of viral replication
while being excluded from regions of virion assembly (3, 4). In
order to determine whether abolition of processing in the
mutant viruses affected the distribution, subcellular localiza-
tion, or ability of the protein to traffic into the replication
complex, we used confocal microscopy to compare the colo-
calization of wild-type and mutated proteins to sites of repli-
cation and assembly. DBT cultures were infected with either
MHV-A59, mock virus, or mutant virus and at 8 hpi were
methanol fixed and dually stained for either nsp8 or nsp10
(depending on the mutant, as above) and nucleocapsid (N),
which colocalizes with sites of active viral replication, or mem-
brane (M), which is targeted to regions of virus assembly.
Regardless of the construct, the nsp8 and nsp10 proteins co-
localized with N in subcellular compartments that were sepa-
rate from M (Fig. 7). These results are identical to those for
wild-type MHV (not shown), indicating that incorporation of
the mutated proteins into the replication complex is not dis-
rupted (3).
DISCUSSION
The nsp7 to nsp10 proteins are highly conserved among, and
perhaps unique to, the family Coronaviridae. Indeed, even the
arteriviruses, another family member of the order Nidovirales,
do not appear to possess homologs to the coronavirus nsp7 to
nsp10 proteins (39). The roles of these proteins in coronavirus
replication are only just beginning to be studied, with the
existing body of data suggesting that they are components of
the replication complex. However, the details of their involve-
ment in replication and RNA synthesis remain to be deter-
mined. This study used an infectious clone of MHV to define
fundamental features of the nsp7 to nsp10 proteins during viral
replication in culture. Each of the four proteins appears to be
critical for viral replication, since deletion of any of the four
protein domains was lethal for RNA synthesis and productive
virus infection. Furthermore, the results indicate that process-
ing of the proteins from each other is necessary for replication,
with the one exception of the nsp9-nsp10 cleavage site. Finally,
we determined that rearrangement of two of the replicase
proteins, nsp7 and nsp8, was not permissive for virus replica-
tion.
To date, only the nsp2 coronavirus replicase protein has
been shown to be dispensable for replication in both MHV-
A59 and SARS-CoV, albeit attenuating in vitro and in vivo
(22). Portions the carboxy-terminal half of MHV nsp1 have
also been deleted in viable mutants (8), but otherwise no full or
partial deletions of replicase protein domains in viable mutants
of any coronavirus have been reported. In contrast, deletion of
each of the nsp7 to nsp10 proteins resulted in a lethal pheno-
type, as evidenced by the lack of recoverable viruses and an
inability to detect subgenomic mRNAs by RT-PCR. These
data suggest that each of the nsp7 to nsp10 proteins may be an
indispensable component of the replication complex, which is
consistent with the highly conserved nature of these proteins.
Alternatively, deletion of nsp coding sequences may sufficiently
alter the structure of the polyprotein template to interfere with
Mpro accessibility to its cleavage sites. Interestingly, an MHV
temperature-sensitive mutant, LA6 (45), contains a mutation
in nsp10 that blocks processing of nsp4 to nsp10 at the non-
permissive temperature (13a), suggesting that mutations or
deletions at the C terminus of ORF1a may disrupt Mpro
activity.
Although it is known that global inhibition of coronavirus
proteinases that process the replicase polyproteins prevents
replication (29), the requirements for each of the 15 cleavage
sites in the ORF1ab polyprotein are not completely deter-
FIG. 7. Immunofluorescence of MHV in cells infected with cleavage mutant virus. Cells were infected with either MHV7/8A, MHV7/8B, or
MHVp15-3, fixed and permeabilized with MeOH, and then dually stained with antibody specific for nsp8 (MHV7/8A and MHV7/8B) or nsp10
(MHVp15-3) and nucleocapsid or membrane protein. The green fluorescent anti-nsp image (A and D) was overlaid with the corresponding red
fluorescent anti-N (B) or anti-M image (E) to determine points of colocalization (yellow) between the nsp and either N, representing localization
with the replication complexes (C), or M, which is excluded from sites of replication (F).
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mined. Cleavage of nsp1, nsp2, and nsp3 has been abolished in
viable MHV mutants (12, 21). Otherwise, little is known of the
requirements for processing, including those for nsp7 to nsp10.
Our results show that changes at cleavage sites between nsp6
and nsp7, nsp7 and nsp8, nsp8 and nsp9, and nsp10 and nsp11
are not replication viable. Lethality could be due to the dis-
ruption of nsp7 to nsp10 proteolytic processing, causing a fail-
ure of precursor, intermediate, or mature protein function
within the replication complex. However, not all of the cleav-
age site mutants were nonviable. Based on genetic analysis,
MHV has two functional nsp7-nsp8 cleavage sites, LQ2A and
LQ2S, and disruption of either of these potential sites failed
to affect replication competence, cleavage patterns, or cellular
localization in vitro. Interestingly, the LQ2A site is conserved
across all coronavirus families, while the LQ2S site is limited
to group II coronaviruses, including MHV, BCoV, HKU1, and
OC43 but not SARS-CoV. Wild-type replication efficiency
when either one or the other site was knocked out suggests that
either or both sites are cleaved during replication. Although we
cannot detect any significant impact on in vitro replication,
variations in N- or C-terminal processing of nsp7-nsp8 may
influence in vivo pathogenesis or affect cell signaling pathways.
However, simultaneous mutation of both sites was lethal, in-
dicating that nsp7 and nsp8 must be fully separated to function
in mRNA synthesis.
The only cleavage site that tolerated inactivation was the
nsp9-nsp10 cleavage site. The mutant MHV9/10 virus pro-
duced an nsp9-nsp10 fusion protein and was highly attenuated
in its replication efficiency. Serial passage of this virus restored
near-wild-type replication fitness but did so without reverting
at the mutated cleavage site or regaining the ability to process
nsp9-nsp10, demonstrating that efficient replication can be
achieved without nsp9-nsp10 proteolytic processing. The data
demonstrate that with the exception of cleavage between the
nsp9 and nsp10 proteins, Mpro processing of the nsp7 to nsp10
proteins is essential in coronavirus RNA transcription and
replication.
Previous work has indicated that nsp7 and nsp8 in solution
form a complex hexadecameric structure that is proposed to
function in processivity and generation of RNA primers for the
RNA replicase (25, 58). If these structures represent those
formed during infection, then they would require cleavage of
nsp7 from nsp8. Similarly, the virus could not replicate when
the relative positions of the genes encoding nsp7 and nsp8
were switched. This loss of viability could be due to an alter-
ation of the precursor polyprotein that interfered with process-
ing or prevented a distinct function associated with the non-
cleaved precursor. It is unclear why only the MHV9/10 mutant
was viable. nsp9 associates with the replication complex, inter-
acting at least with nsp8 (51), and has been shown to possess
single-stranded RNA-binding affinity (3, 15, 51). Nsp10 is
known to associate with several proteins of the replication
complex, including nsp1, nsp5, nsp7, nsp8, and nsp12 (7, 8).
nsp10 has been shown to be critical for the formation of func-
tional replication complexes (45) and has recently been shown
to crystallize to form monomers and homodimers as well as a
complex dodecameric structure when expressed as an nsp10-
nsp11 fusion (28, 50). It is puzzling that this critical protein
with broad interactions with other replicase proteins would
retain its function without full separation from nsp9. Interest-
ingly, mutation of the nsp10-nsp11 cleavage site was nonviable
despite a report that the spherical structure formed by 12 units
of nsp10 was crystallized as an nsp10-nsp11 construct (50).
Collectively, our data indicate that the C-terminal cleavage site
for the nsp10 protein is essential for infectivity, raising doubts
about the biological relevance of the reported nsp10-nsp11
dodecameric crystal structure (50).
Prior to this study, two viable cleavage mutants of corona-
viruses had been reported, as the PLP1-mediated cleavage
sites between nsp1-nsp2 and nsp2-nsp3 were removed in MHV
(12, 21). Loss of cleavage site function resulted in attenuated
replication and suggested that efficient cleavage of nsp1-nsp2
and nsp2-nsp3 was important, but not required, for replication
in tissue culture (12, 21). Indeed, viable mutant virus could be
generated even when PLP1, which solely mediates nsp1-nsp2
and nsp2-nsp3 processing in MHV, was inactivated (21). With
this report, three cleavage sites in the MHV ORF1a polypro-
tein have been shown to be dispensable for replication: nsp1-
nsp2, nsp2-nsp3, and nsp9-nsp10 (12, 21). It is possible that this
reflects the use of these proteins in natural precursors, such as
has been reported for nsp2-nsp3 and nsp4 to nsp10. Thus, the
engineered changes may reproduce some component of the
normal life cycle and at least residual function of these pro-
teins. Interestingly, rearrangement of the nsp7 and nsp8 coding
sequences was lethal, a result that lends support to the idea
that there may be an independent function in replication as-
sociated with the nsp4 to nsp10 precursor (45).
There are still many aspects of coronavirus replication that
are not clearly understood. Several conserved components of
the coronavirus replicase have no known homologs and have
unknown or poorly defined functions. The proteolytic process-
ing of the replicase polyproteins is a critical step in replication
of these viruses, and such processing my provide a level of
regulation over replication in general, such as providing the
molecular switch for altering the output of the replication
complex from negative-strand RNA to that of positive-strand
RNA (5, 44). This work will progress by experimentally pur-
suing new questions defined by these results. Although pro-
cessing of either of the sites at the nsp7-nsp8 boundary had no
impact on virus growth in cell culture, work will be done to
determine whether both sites are required for efficient repli-
cation in animals. Some insight may be gained into nsp7 to
nsp10 function, such as cis versus trans activity, by determining
whether lethal cleavage mutants can complement each other to
form viable replication complexes to rescue virus. The distal
mutations that arose during serial passaging to allow the at-
tenuated MHV9/10 mutant to recover have been identified for
both MHV9/10p15 revertants. MHVp15-1 contained a 5-nu-
cleotide insertion of CTAAT at nucleotide position 65 with the
5 untranslated region (UTR), a Met-to-Leu mutation at
amino acid 225 of nsp2, a His-to-Leu mutation at amino acid
112 of nsp4, a Phe-to-Val mutation in nsp13 at amino acid 145,
a Phe-to-Tyr mutation in the Spike glycoprotein at position
937, and a Ser-to-Ile mutation in ORF6 at amino acid 78.
Mutations found in MHVp15-3 included the same 5-nucleo-
tide insertion within the 5 UTR seen in MHV9/10p15-1, the
His-to-Leu change at amino acid position 112 of nsp4, a Ser-
to-Gly change at amino acid 74 of nsp5, and a Phe-to-Tyr
change at amino acid 937 of S. The changes found for
MHVp15-3 were cloned into the infectious clone of the parent
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MHV9/10, and replication efficiency was restored (data not
shown). Additional work to determine whether the mutations
shared between the two MHV9/10p15 revertants at the 5
UTR, nsp4, and S are sufficient to restore efficient growth is
also planned. The data in this report support existing informa-
tion that the proteins of the 3 C terminus of ORF1a are
critical for replication, establish the importance of processing
in their function, and lay the foundation for future studies
aimed at expanding our understanding of the interactions that
occur between proteins of the coronavirus replication complex.
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